Heart failure affects about 3% of US adults – roughly 6.7 million people aged 20 and older in NHANES 2017–2020 data – and is one of the most common reasons adults over 65 are hospitalized. Despite advances in pharmacotherapy, about 1 in 5 patients is readmitted within 30 days of a heart failure hospitalization – a metric directly influenced by nursing care quality, particularly discharge education and follow-up. For nursing students, heart failure is among the highest-yield NCLEX topics and one of the most frequently encountered diagnoses across all clinical settings. This reference covers classification, pathophysiology, assessment, nursing interventions, pharmacology (including newer agents), acute decompensation management, and patient education.
Cross-reference this page with the atrial fibrillation nursing reference – AFib is both a cause and consequence of heart failure – and the hypertension nursing reference, since hypertension is the leading cause of HFpEF and a major driver of cardiac remodeling.
| Key clinical facts | Heart failure reference |
|---|---|
| HFrEF ejection fraction | ≤ 40% (2022 AHA/ACC/HFSA) |
| HFmrEF ejection fraction | 41–49% (mildly reduced) |
| HFpEF ejection fraction | ≥ 50% |
| HFimpEF | Prior EF ≤ 40%, now > 40% – keep GDMT going |
| NYHA classes | I (no symptoms) → IV (symptoms at rest) |
| AHA/ACC stages | A (at risk) → D (advanced) |
| BNP: HF likely | > 400 pg/mL; > 100 pg/mL = possible HF |
| NT-proBNP: HF unlikely | < 300 pg/mL (all ages) |
| Daily weight notification threshold | 2 lb gain in 24 hours OR 5 lb gain in 1 week |
| Fluid restriction (when prescribed) | Commonly 1.5–2 L/day; guideline benefit uncertain (2b, advanced HF with hyponatremia) |
| Sodium | Guideline: avoid excessive intake (no set number); 2 g/day is a common order |
| HOB position (acute HF) | 30–45°; High Fowler (60–90°) for acute distress |
| HFrEF "four pillars" | ARNi (or ACEi/ARB) + evidence-based beta-blocker + MRA + SGLT2i |
| Do NOT start in acute decompensation | Beta-blockers (start once stable; continue an existing beta-blocker unless shock or marked hypoperfusion) |
| 36-hour ACEi washout required before | Sacubitril/valsartan (Entresto) |
| Digoxin therapeutic range (HF) | 0.5–0.9 ng/mL (lower than historical 1.0–2.0) |
Classification: HFrEF vs HFpEF
Heart failure is classified primarily by ejection fraction (EF) – the percentage of blood ejected from the left ventricle with each contraction, measured on echocardiography.
| Feature | HFrEF (reduced EF) | HFmrEF (mildly reduced EF) | HFpEF (preserved EF) |
|---|---|---|---|
| Ejection fraction | ≤ 40% | 41–49% | ≥ 50% |
| Primary defect | Systolic dysfunction – ventricle contracts poorly | Mixed systolic and diastolic features | Diastolic dysfunction – ventricle cannot relax and fill |
| Typical patient | History of MI, dilated cardiomyopathy, younger men | Intermediate – overlapping features | Elderly, female, obesity, hypertension, diabetes, atrial fibrillation |
| Cardiac output at rest | Low – reduced stroke volume | Variable | Often normal at rest; impaired with exertion |
| Disease-modifying drugs | Four pillars, all class 1: ARNi (or ACEi/ARB), evidence-based beta-blocker, MRA, SGLT2i | SGLT2i (2a); beta-blocker, ARNi/ACEi/ARB and MRA may be considered (2b), especially at the lower end of the EF range; finerenone FDA-approved 2025 for LVEF ≥ 40% | Diuretics for congestion; SGLT2i (2a); MRA, ARNi or ARB may be considered (2b); finerenone FDA-approved 2025 (FINEARTS-HF reduced worsening HF events, no CV death difference) |
| Key management focus | Neurohormonal blockade + ICD/CRT if indicated | Treat underlying causes; optimize comorbidities | Congestion control + aggressive comorbidity management (HTN, AF, DM, obesity) |
Clinical insight: HFpEF accounts for about half of all heart failure. It is harder to treat than HFrEF – no drug has yet clearly reduced mortality in HFpEF, although SGLT2 inhibitors and finerenone reduce worsening heart failure events – and its prevalence continues to grow with an aging, more obese population.
HFimpEF (heart failure with improved EF): The 2022 guideline adds this category for patients whose EF was ≤ 40% and has since risen above 40%. Improvement is usually remission rather than cure, so GDMT should be continued; stopping it leads to relapse in many patients.
NYHA functional classification
The New York Heart Association (NYHA) classification describes symptom burden and guides medication and device selection. The 2022 guideline’s MRA recommendation, for example, applies to HFrEF with NYHA class II–IV symptoms. Unlike the ACC/AHA stage, NYHA class can move up or down as symptoms change. NCLEX questions frequently test NYHA class definitions.
| NYHA class | Symptoms | Functional limitation | Clinical significance |
|---|---|---|---|
| Class I | No symptoms with ordinary physical activity | None | All stage B (pre-HF) patients are class I; a stage C patient whose symptoms resolve on treatment is also class I but stays stage C |
| Class II | Symptoms (dyspnea, fatigue, palpitations) with moderate exertion (e.g., climbing stairs, walking uphill) | Slight limitation; comfortable at rest | Mild HF – initiate neurohormonal therapy |
| Class III | Symptoms with minimal exertion (e.g., walking on a flat surface, light housework) | Marked limitation; comfortable only at rest | Moderate HF – optimize pharmacotherapy; consider ICD/CRT eligibility |
| Class IV | Symptoms at rest; unable to perform any activity without discomfort | Severely limited; bed or chair bound | Severe/advanced HF – palliative care discussions; LVAD or transplant evaluation |
AHA/ACC staging
The AHA/ACC staging system (2022 guidelines, A–D) complements NYHA by tracking disease progression. Unlike NYHA class, a patient does not move back to an earlier stage: someone in stage C whose symptoms resolve remains stage C and keeps their treatment. If all symptoms, signs and structural abnormalities resolve, the 2022 guideline calls this “HF in remission.”
| Stage | Definition | Examples |
|---|---|---|
| Stage A | At risk for HF; no structural disease or symptoms | Hypertension, diabetes, obesity, known cardiotoxin exposure, family history of cardiomyopathy |
| Stage B | Pre-HF: no symptoms to date, plus structural disease, raised filling pressures, or (with risk factors) elevated natriuretic peptides or troponin | Reduced EF on echo, wall motion abnormality after MI, LVH, valve disease – patient has never had HF symptoms |
| Stage C | Symptomatic HF: structural disease with current or prior symptoms | Dyspnea, fatigue, edema in a patient with known structural heart disease |
| Stage D | Advanced HF: marked symptoms that interfere with daily life, with recurrent hospitalizations despite attempts to optimize GDMT | Requiring repeated hospitalization; persistent NYHA IV symptoms; evaluation for LVAD, transplant, or hospice |
Pathophysiology
Heart failure is a clinical syndrome in which the heart cannot pump sufficient blood to meet the body’s metabolic needs, or can do so only at the cost of abnormally elevated filling pressures. Understanding why compensatory mechanisms eventually fail explains both symptoms and pharmacotherapy.
Compensatory mechanisms
When cardiac output falls, three overlapping responses are activated:
Frank-Starling mechanism: Increased preload (venous return) stretches the ventricle, and up to a point, this increases contractile force. Beyond the optimal stretch, however, the ventricle becomes overfilled and contractility falls – the ascending Starling curve becomes a descending one. This is why volume overload worsens rather than corrects cardiac output in heart failure.
Sympathetic nervous system (SNS) activation: Reduced cardiac output triggers baroreceptor-mediated catecholamine release (epinephrine, norepinephrine). This increases heart rate, contractility, and causes peripheral vasoconstriction. Short-term these effects maintain perfusion pressure; long-term, SNS overdrive increases myocardial oxygen demand, causes direct myocardial toxicity, and promotes maladaptive remodeling – which is why beta-blockers improve survival in HFrEF despite initially seeming counterintuitive.
RAAS activation: Reduced renal perfusion pressure triggers renin release from the juxtaglomerular cells. Renin converts angiotensinogen to angiotensin I → angiotensin II (via ACE). Angiotensin II causes potent vasoconstriction and stimulates aldosterone secretion from the adrenal cortex. Aldosterone promotes sodium and water retention in the renal collecting duct, expanding blood volume. Chronically, this causes progressive volume overload, worsens congestion, and drives cardiac fibrosis – explaining why ACE inhibitors, ARBs, and aldosterone antagonists form the pharmacologic backbone of HFrEF treatment.
Forward vs backward failure
These concepts explain which direction symptoms originate from:
- Forward failure: Insufficient cardiac output delivered to the periphery → fatigue, weakness, poor exercise tolerance, cool extremities, decreased urine output, altered cognition
- Backward failure: Blood backs up behind the failing ventricle → elevated filling pressures and venous congestion. Left-sided backward failure → pulmonary venous congestion. Right-sided backward failure → systemic venous congestion.
Most patients experience both simultaneously. When left heart failure is sustained, elevated pulmonary arterial pressures eventually strain the right ventricle, producing biventricular failure with combined findings.
Decompensation triggers
Patients with compensated chronic heart failure decompensate when a physiologic stress overwhelms remaining cardiac reserve. Common triggers nurses should recognize:
- Dietary sodium excess or fluid intake exceeding restriction
- Medication non-adherence (particularly diuretics and neurohormonal agents)
- New-onset or rapid-ventricular-response atrial fibrillation (see AFib nursing reference)
- Sepsis – myocardial depression plus systemic vasodilation (see sepsis nursing reference)
- Cardiac ischemia or new MI
- Pulmonary embolism
- Worsening renal function (cardiorenal syndrome)
- Hypertensive crisis (see hypertension nursing reference)
- Thyroid dysfunction (hyperthyroidism increases cardiac demand)
- Anemia – decreased oxygen delivery demands increased cardiac output
Clinical assessment
Left vs right heart failure findings
The side of the heart that fails determines the direction of congestion.
| Assessment finding | Left heart failure | Right heart failure |
|---|---|---|
| Dyspnea (exertional) | Yes – cardinal symptom; pulmonary venous congestion impairs gas exchange | Mild or absent unless biventricular |
| Orthopnea | Yes – lying flat redistributes fluid from dependent areas into pulmonary circulation; quantify by number of pillows | Absent unless biventricular |
| Paroxysmal nocturnal dyspnea (PND) | Yes – patient awakens 1–3 hours after sleeping with severe dyspnea; sits up or goes to window for relief | Absent unless biventricular |
| Bibasilar crackles | Yes – alveolar fluid; do not clear with coughing; distinguish from coarse crackles of secretions | Absent (lungs not congested) |
| S3 gallop (ventricular) | Present at apex with bell of stethoscope – hallmark of elevated left-sided filling pressures; suggests EF < 40% or acute decompensation | May be present at left sternal border |
| Jugular venous distension (JVD) | Late, with biventricular failure | Yes – hallmark; assess at 45°; venous column > 3–4 cm above sternal angle is abnormal |
| Peripheral edema | Absent unless biventricular | Yes – bilateral pitting; begins at ankles, progresses to legs, thighs, sacrum, scrotum in severe disease; grade 1+ to 4+ |
| Hepatomegaly / hepatojugular reflux (HJR) | Hepatomegaly absent; a positive HJR also suggests raised left-sided filling pressure | Yes – apply firm, sustained pressure over the mid-abdomen or right upper quadrant for at least 10 seconds; positive if the JVP rises more than 3 cm and stays up during compression (some sources use ≥ 4 cm) |
| Ascites | Absent | Yes – advanced right failure; elevated hepatic and portal venous pressures |
| Nausea, anorexia, bloating | Absent or mild | Yes – gut edema from congested mesenteric and hepatic veins |
| Pleural effusion | Common – bilateral, right-predominant; transudative by Light's criteria | Less common in isolation |
Key physical exam findings
S3 gallop: Often called the “Ken-tuc-ky” gallop (S1–S2–S3). Heard best at the apex with the bell of the stethoscope in the left lateral decubitus position. Represents rapid ventricular filling against an already elevated filling pressure. In adults, an S3 is pathological and one of the most specific signs of systolic HF or elevated left atrial pressure.
JVD assessment: Position the patient at 45°. Use tangential lighting. The external jugular vein (or the pulsating column in the internal jugular) should not be visible above the clavicle at 45° in a healthy patient. Identify the top of the venous column and measure vertically to the sternal angle; add 5 cm (the fixed sternal angle-to-right atrium distance). A total CVP estimate > 8–10 cm H₂O indicates elevated right-sided filling pressure.
Pulmonary assessment: Crackles in heart failure are typically fine, bibasilar, and inspiratory. They do not clear with coughing (unlike secretion-related coarse crackles). In severe pulmonary edema, crackles extend to mid-lung or the entire lung field. Wheezing (“cardiac asthma”) can occur from airway edema.
Hemodynamic parameters to monitor:
- Blood pressure – hypotension suggests forward failure and cardiogenic shock risk; hypertension may indicate a hypertensive trigger
- Heart rate – tachycardia is compensatory; look for new AFib (see EKG interpretation cheat sheet)
- Respiratory rate – tachypnea with SpO2 decline indicates worsening pulmonary edema
- Urine output – target ≥ 0.5 mL/kg/hr; oliguria in decompensation may indicate cardiorenal syndrome
- Daily weight – a key early indicator of fluid retention
Diagnostic findings
BNP and NT-proBNP
B-type natriuretic peptide (BNP) is released from ventricular myocytes in response to wall stretch from volume overload and elevated filling pressures. It is the most important biomarker for diagnosing and monitoring heart failure. Reference ranges are in the nursing lab values cheat sheet.
- BNP < 100 pg/mL: Heart failure unlikely
- BNP 100–400 pg/mL: Intermediate – clinical context required
- BNP > 400 pg/mL: Heart failure likely; the higher the level on admission, the higher the in-hospital mortality risk
- NT-proBNP < 300 pg/mL: Heart failure unlikely (all ages)
- NT-proBNP thresholds for HF likely: Age < 50 → > 450 pg/mL; age 50–75 → > 900 pg/mL; age > 75 → > 1,800 pg/mL
Critical caveat: Patients on sacubitril/valsartan (Entresto) have elevated BNP levels because neprilysin – the enzyme that degrades natriuretic peptides – is inhibited. In these patients, use NT-proBNP, not BNP, for monitoring.
BNP is also elevated in renal failure (decreased clearance). Obesity lowers both BNP and NT-proBNP, which reduces their sensitivity (2022 AHA/ACC/HFSA), so a “normal” result in an obese patient does not rule out heart failure. BNP and NT-proBNP cut-points are not interchangeable. Always interpret in clinical context.
Echocardiography
Transthoracic echocardiography (TTE) is the essential diagnostic study. It measures EF (defining HFrEF vs HFpEF), identifies wall motion abnormalities from prior ischemia, evaluates valve function, estimates pulmonary artery pressures, and detects pericardial effusion. Every new heart failure diagnosis requires an echo. EF measurement is the basis for all pharmacotherapy and device therapy decisions.
Chest X-ray
CXR findings correlate with severity of congestion:
- Cardiomegaly: Cardiothoracic ratio > 0.5 on PA projection
- Pulmonary vascular redistribution (cephalization): Upper lobe pulmonary vessels more prominent than lower lobe – early sign of elevated left atrial pressure
- Kerley B lines: Short horizontal lines perpendicular to the pleural surface at the lung bases – represent fluid in interlobular septa
- Interstitial edema: Hazy, indistinct vascular markings; “ground glass” appearance
- Bat-wing (butterfly) infiltrates: Bilateral perihilar haziness – classic pattern of acute alveolar pulmonary edema
- Pleural effusions: Blunting of costophrenic angles; usually bilateral, right-predominant
Laboratory panel
| Test | What to monitor | Clinical significance in HF |
|---|---|---|
| BMP (Na, K, Cr, BUN) | Electrolytes, renal function | Hyponatremia = severe HF + poor prognosis; hypokalemia increases digoxin toxicity; rising creatinine with diuresis = cardiorenal syndrome |
| BNP or NT-proBNP | HF biomarker | Diagnosis, severity, and treatment response |
| CBC | Hemoglobin | Anemia worsens symptoms and is a decompensation trigger |
| LFTs (AST, ALT, bilirubin) | Hepatic congestion | Elevated in right heart failure; cardiogenic cirrhosis in chronic severe RHF |
| Troponin I or T | Myocardial injury | Elevated in acute decompensation (chronic stretch); markedly elevated if MI is the trigger |
| TSH | Thyroid function | Hypothyroidism causes dilated cardiomyopathy; hyperthyroidism precipitates decompensation |
| Urinalysis | Proteinuria, specific gravity | Cardiorenal syndrome; nephrotic proteinuria from venous congestion |
Nursing interventions
The following priority-ordered interventions address the core physiologic derangements in heart failure: volume overload, impaired oxygenation, electrolyte shifts, and deconditioning risk.
| Priority | Intervention | Rationale / key parameters |
|---|---|---|
| 1 | Position head of bed 30–45°; High Fowler (60–90°) or tripod in acute distress | Reduces preload by promoting venous pooling in lower extremities; improves lung compliance and respiratory excursion; decreases orthopnea |
| 2 | Supplemental oxygen for hypoxemia (SpO2 < 90% or PaO2 < 60 mmHg, ESC 2021) | Do not give oxygen routinely to patients who are not hypoxemic. Titrate to the ordered range – commonly 94–98%, or 88–92% if at risk of hypercapnic respiratory failure (BTS). Prepare for CPAP/BiPAP when respiratory distress persists (RR > 25/min, SpO2 < 90%) – improves gas exchange and reduces intubation |
| 3 | Daily weights – same time (morning, after voiding, before eating), same scale, same clothing | Key early indicator of fluid retention. Notify provider for ≥ 2 lb gain in 24 hours OR ≥ 5 lb gain in 1 week – both thresholds, not just one |
| 4 | Strict intake and output (I&O) monitoring | Report urine output < 0.5 mL/kg/hr. Inadequate diuresis despite loop diuretics may indicate cardiorenal syndrome or diuretic resistance. Track all fluid sources including ice chips and tube feedings |
| 5 | Fluid restriction when prescribed (commonly 1.5–2 L/day, all fluid sources) | Usually ordered for hyponatremia or congestion that persists despite diuretics. The evidence is low quality: the 2022 guideline rates the benefit as uncertain (2b) in advanced HF with hyponatremia. When ordered, all liquids count, including IV fluids and medication diluents, ice chips, gelatin, and ice cream. Educate the patient to use small cups and spread intake through the day |
| 6 | Continuous cardiac monitoring; 12-lead EKG | Identify new-onset AFib (major decompensation trigger), QT prolongation from electrolyte disturbances, ventricular arrhythmias. Consult [EKG interpretation cheat sheet](/nursing-tips/ekg-interpretation-cheat-sheet/) for rhythm identification |
| 7 | Electrolyte monitoring and replacement | Loop diuretics cause potassium and magnesium wasting. Hypokalemia increases digoxin toxicity risk and arrhythmia risk. Aldosterone antagonists cause hyperkalemia. Check BMP before each diuretic dose when unstable. See [electrolyte imbalances nursing reference](/nursing-tips/electrolyte-imbalances-nursing/) |
| 8 | Administer diuretics promptly; monitor response | IV furosemide onset: within 5 minutes; peak effect within the first 30 minutes; duration about 2 hours (label). For patients already on a loop diuretic, the starting IV dose is typically 1–2 times the home oral daily dose (ESC 2021). ESC 2021 treats a spot urine sodium ≥ 50–70 mEq/L at 2 hours or urine output ≥ 100–150 mL/h over the first 6 hours as an adequate response; report anything less. Give high-dose IV furosemide no faster than 4 mg/min (ototoxicity) |
| 9 | Activity: bed rest during acute decompensation; progressive ambulation once stable | Restrict to bed with bedside commode during active fluid overload. Once hemodynamically stable, initiate progressive ambulation – deconditioning occurs rapidly. Cardiac rehabilitation reduces readmission and improves functional capacity |
| 10 | Skin integrity: assess every shift; protect edematous areas | Dependent edema = high skin breakdown risk over shins, ankles, sacrum, scrotum. Apply moisture barrier on intact skin. Reposition every 2 hours. Elevate legs when not ambulating (avoid leg elevation in patients with acute dyspnea who cannot tolerate increased venous return). Compression stockings contraindicated over weeping or blistered skin |
| 11 | Fall prevention | Orthostatic hypotension risk from diuresis + vasodilating medications; assess before ambulation. Apply fall precautions. Call light within reach; non-slip footwear. Weakness and fatigue compound fall risk |
| 12 | Sodium: avoid excessive intake; follow the ordered limit (often 2 g/day) | The 2022 guideline (2a) recommends avoiding excessive sodium to reduce congestive symptoms but sets no number. In SODIUM-HF (2022), a < 1,500 mg/day diet did not reduce death or hospital visits compared with usual care, and very strict restriction can cause poor nutrition. Reinforce with a dietitian consult; most processed and restaurant food is very high in sodium |
Pharmacology
| Drug class | Prototype / examples | Mechanism | Nursing considerations | Key adverse effects |
|---|---|---|---|---|
| Loop diuretics | Furosemide (Lasix), bumetanide, torsemide | Inhibit Na-K-2Cl cotransporter in the loop of Henle → natriuresis and diuresis; reduce volume overload (preload reduction) | Monitor K+, Mg2+, creatinine, BUN. Weigh daily. IV onset: 5–10 min. Torsemide has better oral bioavailability than furosemide (80–100% vs 40–60%); preferred in patients with gut edema reducing absorption. Hold if hypovolemic; report output < 0.5 mL/kg/hr | Hypokalemia, hypomagnesemia, hyponatremia, dehydration, ototoxicity (high doses or rapid IV push), azotemia |
| ACE inhibitors | Lisinopril, enalapril, ramipril, captopril | Block conversion of angiotensin I to angiotensin II → reduced vasoconstriction and aldosterone → decreased preload and afterload; reduce cardiac remodeling; proven mortality benefit in HFrEF | Hold if K+ > 5.5 mEq/L, SBP < 90 mmHg, or creatinine rises > 30% from baseline. Boxed warning for fetal toxicity: stop as soon as pregnancy is detected (the same warning applies to ARBs and sacubitril/valsartan; current labels no longer use the old A/B/C/D/X letter categories). Discontinue immediately if angioedema develops. Dry persistent cough is a class effect from bradykinin accumulation – switch to ARB or ARNi if intolerable | Dry cough (common), hyperkalemia, hypotension (first-dose), angioedema (rare but dangerous), acute kidney injury |
| ARBs | Losartan, candesartan, valsartan | Block angiotensin II AT1 receptor directly; equivalent hemodynamic effects to ACEi; no bradykinin accumulation → no cough; used when ACEi is intolerable or as alternative in HFrEF | Same monitoring as ACEi: K+, BP, creatinine. Do NOT combine ACEi + ARB (no additional benefit; increased adverse effects). Do NOT use standalone valsartan in patients on sacubitril/valsartan – different products, different formulations | Hyperkalemia, hypotension, acute kidney injury; angioedema rare but possible (especially if prior ACEi angioedema) |
| Angiotensin receptor-neprilysin inhibitor (ARNi) | Sacubitril/valsartan (Entresto) | Sacubitril inhibits neprilysin (which degrades natriuretic peptides and bradykinin), amplifying their vasodilatory and natriuretic effects; valsartan blocks AT1 receptor. Superior to enalapril in reducing mortality in HFrEF (PARADIGM-HF trial). The 2022 guideline recommends ARNi in NYHA II–III HFrEF and replacing an ACEi or ARB with ARNi when tolerated | Never combine with ACE inhibitor – blocking both bradykinin breakdown pathways sharply raises the risk of severe angioedema. Require a mandatory 36-hour ACEi washout before starting. Monitor BP (hypotension common, especially first dose), K+, renal function. BNP is unreliable on Entresto – neprilysin inhibition elevates BNP artificially; use NT-proBNP for monitoring | Hypotension, hyperkalemia, renal dysfunction, angioedema (especially within 36h of ACEi) |
| Beta-blockers | Carvedilol, metoprolol succinate (Toprol XL), bisoprolol | Block catecholamine effects on heart → reduce heart rate, myocardial oxygen demand; long-term: reverse maladaptive remodeling, improve EF and survival in HFrEF | Only three agents have mortality benefit in HFrEF: carvedilol, metoprolol succinate (extended-release), and bisoprolol. Metoprolol tartrate (immediate-release) is NOT approved for HFrEF and is not equivalent – clarify orders. Do NOT initiate during acute decompensated HF; can precipitate cardiogenic shock. Start once the patient is stable and euvolemic. A patient already on a beta-blocker should usually continue it in hospital (stopping it is linked to higher mortality); dose reduction is reserved for marked volume overload, low output or shock. Start low and titrate toward target doses; the guideline allows GDMT adjustments as often as every 1–2 weeks. Common hold parameters: HR < 60 or SBP < 90 – follow the written order | Bradycardia, hypotension, fatigue, bronchospasm (use cardioselective agent with caution in COPD/asthma), masking hypoglycemia symptoms |
| Aldosterone antagonists (MRAs) | Spironolactone (Aldactone), eplerenone (Inspra) | Block aldosterone at distal tubule → potassium-sparing diuresis; reduce cardiac fibrosis and remodeling; mortality benefit in HFrEF (RALES for spironolactone in severe HFrEF; EMPHASIS-HF for eplerenone in mild symptoms; EPHESUS for eplerenone after MI with EF ≤ 40%). Finerenone (Kerendia), a nonsteroidal MRA, is FDA-approved (July 2025) for HF with LVEF ≥ 40% based on FINEARTS-HF | Monitor K+ closely – hyperkalemia risk especially with ACEi/ARB/ARNi. 2022 guideline: start only if eGFR > 30 mL/min/1.73 m² and K+ < 5.0 mEq/L; recheck K+ and renal function at about 1 week and 4 weeks, then every 6 months. Spironolactone causes gynecomastia in men (anti-androgenic effect) – switch to eplerenone if problematic. Eplerenone is more selective, fewer hormonal side effects but more expensive | Hyperkalemia, renal dysfunction, gynecomastia / menstrual irregularities (spironolactone) |
| SGLT2 inhibitors | Dapagliflozin (Farxiga), empagliflozin (Jardiance) | Inhibit sodium-glucose cotransporter-2 in proximal tubule → glucosuria + natriuresis + osmotic diuresis; multiple cardioprotective mechanisms including reduced inflammation, myocardial fibrosis, and intracardiac pressure. Reduce HF hospitalizations and cardiovascular death (DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved trials) | Indicated for heart failure regardless of diabetes status. FDA approvals for HFrEF: dapagliflozin 2020, empagliflozin 2021. Both now cover heart failure across the EF range: empagliflozin from February 2022 (EMPEROR-Preserved) and dapagliflozin from May 2023 (DELIVER). Monitor for genitourinary infections (candidal vaginitis, balanitis, UTIs). Risk of euglycemic DKA – check glucose AND ketones if patient is unwell. Labels: withhold for at least 3 days before surgery or procedures that need prolonged fasting, and restart once eating and stable. Dapagliflozin should not be started at eGFR < 25 mL/min/1.73 m²; empagliflozin trials did not enroll patients below eGFR 20 | Genitourinary infections, euglycemic DKA, urinary frequency, mild hypotension, Fournier's gangrene (rare) |
| Digoxin | Digoxin (Lanoxin) | Inhibits Na-K-ATPase pump → increased intracellular calcium → positive inotropy; slows AV nodal conduction → rate control in AF with HF | Narrow therapeutic index: therapeutic range for HF is 0.5–0.9 ng/mL (lower than older recommendations of 1.0–2.0 ng/mL – higher levels do not improve outcomes and increase toxicity). Hold if apical pulse < 60 bpm. Hypokalemia dramatically potentiates toxicity – check K+ before every dose when diuretics are co-prescribed. Renal dosing adjustment required | Toxicity: nausea, vomiting, anorexia, visual disturbances (yellow-green halos, blurred vision), bradycardia, [AV heart block](/nursing-tips/heart-block-poem/), arrhythmias (PVCs, bidirectional VT). Antidote: digoxin immune Fab (DigiFab, ovine) for life-threatening toxicity; the older Digibind brand is no longer sold in the US |
The four pillars of HFrEF therapy: The 2022 AHA/ACC/HFSA guideline gives a class 1 recommendation to four drug classes in symptomatic HFrEF: an ARNi (or ACEi/ARB if ARNi is not possible), one of the three evidence-based beta-blockers, an MRA, and an SGLT2 inhibitor. Loop diuretics relieve congestion but are not one of the pillars. Speed matters after a hospitalization: in STRONG-HF (2022), which enrolled patients hospitalized for acute HF across the EF range, raising RAS blockers, beta-blockers and MRAs to full doses within 2 weeks of discharge, with four follow-up visits over 2 months, cut 180-day death or HF readmission from 23.3% to 15.2% compared with usual care. For nurses, this means checking BP, heart rate, potassium and creatinine at each titration step, and reinforcing that patients should not stop a drug because the dose went up.
Critical NCLEX distinction: Metoprolol succinate (extended-release) has proven HFrEF mortality benefit. Metoprolol tartrate (immediate-release) does NOT share this indication and is not interchangeable. Always clarify the formulation in orders.
ARNi washout rule: Never start sacubitril/valsartan without confirming the patient has been off all ACE inhibitors for at least 36 hours. Combining them with ACEi – even with an overlap of hours – dramatically increases angioedema risk.
Acute decompensated heart failure (ADHF)
Acute decompensated heart failure occurs when the compensated state fails and the patient develops rapid hemodynamic deterioration, pulmonary edema, or end-organ hypoperfusion. Recognizing ADHF early and initiating the correct interventions within the first hour is critical.
Recognition
Key ADHF presentations:
- Worsening dyspnea, orthopnea, PND over days (gradual decompensation – most common)
- Acute flash pulmonary edema (sudden onset severe dyspnea with pink frothy sputum)
- Fatigue and decreased urine output without significant edema (low-output syndrome)
- Weight gain of > 5 lbs over 1 week
Nohria-Stevenson hemodynamic profiles (warm/cold, wet/dry)
One of the most useful bedside frameworks for ADHF is the clinical profile scheme published by Nohria, Stevenson and colleagues in 2003, which the 2022 AHA/ACC/HFSA guideline cites for initial triage of congestion and perfusion. It sorts patients on two axes: perfusion adequacy (warm vs cold) and congestion status (wet vs dry). It is often mislabeled “Forrester.” The Forrester subsets (1976) used the same 2×2 idea but were defined by invasive measurements – pulmonary capillary wedge pressure above 18 mmHg and cardiac index below 2.2 L/min/m² – in patients after acute MI. In Nohria’s 452 admitted patients, warm and wet was the most common profile (49%) and cold and dry the rarest (about 4%), and the wet profiles carried the highest risk of death or urgent transplant at 1 year.
| Subset | Perfusion | Congestion | Clinical picture | Management principle |
|---|---|---|---|---|
| Warm and dry (profile A) | Adequate | None | Compensated – outpatient stable HF | Optimize oral regimen; no acute IV therapy needed |
| Warm and wet (profile B) | Adequate | Yes | Most common ADHF profile: dyspnea, crackles, edema; adequate perfusion pressure | Diuresis ± vasodilators (nitroglycerin/nitroprusside); better outlook than cold and wet, but worse than warm and dry |
| Cold and dry (profile L) | Impaired | Minimal | Low output without congestion: fatigue, cool extremities, hypotension; often diuretic-depleted or cardiogenic | Careful fluid challenge if volume-depleted; inotropes for confirmed low-output states; avoid aggressive diuresis |
| Cold and wet (profile C) | Impaired | Yes | Cardiogenic shock picture: hypotension + congestion; worst prognosis; poor end-organ perfusion | Inotropes (dobutamine, milrinone); vasopressors if needed; consider mechanical support (IABP, Impella); ICU-level care |
Why this matters clinically: A “cold and wet” patient who is aggressively diuresed without addressing the low-output state will develop worsening renal failure, hypotension, and clinical deterioration. The hemodynamic subset guides whether the priority is diuresis, vasodilation, or inotropic support.
LMNOP protocol – with an important update
The LMNOP mnemonic is still taught in nursing programs for managing acute pulmonary edema:
- L – Loop diuretic (furosemide IV): Reduces preload through diuresis; early IV administration is a priority
- M – Morphine: Historically used to reduce preload and anxiety. Morphine is no longer routinely recommended for ADHF. Retrospective studies (including ADHERE registry data) found morphine associated with increased rates of mechanical ventilation, ICU admission, and mortality. The 2021 ESC guideline says routine opiate use is not recommended (class III), except in selected patients with severe or intractable pain or anxiety. It may still be used in palliative/comfort contexts, but is not a first-line ADHF intervention.
- N – Nitrates (nitroglycerin IV): Potent venodilator at low doses; arterial dilator at higher doses – reduces preload and afterload; rapid onset; effective for hypertensive acute pulmonary edema
- O – Oxygen: Only for hypoxemia (SpO2 < 90% or PaO2 < 60 mmHg, ESC 2021), titrated to the ordered range; CPAP/BiPAP early for respiratory distress
- P – Position (upright): High Fowler or dangling legs; maximizes respiratory excursion and reduces venous return
Nursing priorities in ADHF:
- Upright position, supplemental O2 / NIV
- Large-bore IV access (two peripheral IVs if possible)
- Continuous cardiac monitoring + 12-lead EKG
- Stat BNP, BMP, troponin, ABG (see ABG interpretation reference)
- Administer IV furosemide and vasodilators as ordered
- Strict hourly I&O; assess urine output response within 60 minutes of diuretic
- Prepare for intubation if no response to NIV
Patient education
Discharge education is among the most impactful nursing interventions for reducing heart failure readmissions. The most effective teaching approach is teach-back – ask the patient to explain instructions in their own words.
Daily weight monitoring:
- Weigh every morning after waking and voiding, before eating, in similar clothing
- Record the weight in a logbook or home monitoring app
- Call your provider if you gain 2 lbs in one day or 5 lbs in one week
- Do not wait for shortness of breath – weight gain is an earlier warning sign
When to call the provider or go to the emergency department:
- Weight gain of 2 lbs in 24 hours or 5 lbs in 1 week
- Increased shortness of breath, especially lying flat or at rest
- Waking up at night unable to breathe
- Legs becoming more swollen
- Feeling dizzy or faint
- New irregular heartbeat
- Reduced urine output
Low-sodium diet (follow the limit your provider sets, often 2 g/day):
- Most processed foods, canned soups, and restaurant meals far exceed safe sodium limits
- Read all food labels: the FDA treats 5% Daily Value or less of sodium per serving as low and 20% or more as high
- Use herbs and spices for flavor instead of salt; avoid salt substitutes containing potassium chloride if on ACEi/ARB/MRA (hyperkalemia risk)
- Avoid fast food, deli meats, pickled foods, and salty snacks
Fluid restriction (1.5–2 L/day when prescribed):
- Includes all liquids: water, juice, milk, coffee, tea, soup, ice chips, gelatin, ice cream
- Use small cups; spread fluid intake across the day
- Sucking on ice chips or hard candy can relieve thirst without significant fluid intake
Medication adherence:
- Do not skip doses, especially diuretics and heart failure medications
- Never stop beta-blockers abruptly without provider guidance – rebound tachycardia and hypertension
- Know the names and purposes of each medication
- Bring a medication list to all appointments and hospitalizations
Activity guidelines:
- Gradually increase activity as tolerated; report dyspnea, chest pain, or palpitations with activity
- Avoid activities during the hottest part of the day; heat causes vasodilation and can worsen hypotension
- Cardiac rehabilitation is available and improves long-term outcomes – ask your provider for a referral
- Plan rest periods between activities; stop before feeling exhausted
NCLEX-style practice questions
Question 1
A nurse is caring for a patient admitted with acute decompensated heart failure. Assessment findings include dyspnea, orthopnea, bibasilar crackles, and an S3 gallop. Which is the nurse’s priority intervention?
A) Administer oral furosemide as scheduled B) Elevate the head of bed to 30–45° and apply supplemental oxygen C) Insert a urinary catheter for strict I&O D) Obtain a stat 12-lead EKG
Answer: B – position and oxygenation are the immediate priorities
Rationale: In acute decompensated left heart failure with dyspnea and crackles, positioning the patient upright reduces preload (venous return), improves lung compliance, and decreases work of breathing. Supplemental oxygen corrects the hypoxemia expected with pulmonary congestion (titrate to the ordered SpO2 range). These interventions can be initiated immediately without a physician order. Oral furosemide (A) is appropriate but IV is preferred in acute decompensation for faster diuresis. Urinary catheter (C) and EKG (D) are important but not the first priority over addressing airway/breathing/circulation – the ABCs.
Question 2
A physician orders metoprolol tartrate 25 mg PO BID for a patient with a new diagnosis of HFrEF (EF 30%). The nurse should take which action?
A) Administer the medication as ordered B) Hold the medication – beta-blockers are contraindicated in all heart failure C) Clarify the order – metoprolol succinate (extended-release) is the approved HFrEF formulation, not tartrate D) Administer metoprolol tartrate and monitor closely for bradycardia
Answer: C – clarify the formulation
Rationale: Only three beta-blockers have proven mortality benefit in HFrEF: carvedilol, metoprolol succinate (extended-release, Toprol XL), and bisoprolol. Metoprolol tartrate (immediate-release) is NOT approved for HFrEF and does not carry the same evidence. This is a medication safety issue – clarifying the order is the correct action. Beta-blockers are not contraindicated in stable HFrEF (B is wrong) but must not be initiated during acute decompensation.
Question 3
A patient with HFrEF was on lisinopril for 2 years. The provider discontinues lisinopril today and plans to start sacubitril/valsartan (Entresto) to improve outcomes. The nurse should plan to administer the first Entresto dose at what time?
A) Tonight – start as soon as the lisinopril is discontinued B) Tomorrow morning – 12 hours is an adequate washout period C) In 36 hours – a mandatory washout period from ACE inhibitors is required D) In 7 days – Entresto cannot be started within 1 week of ACEi discontinuation
Answer: C – 36-hour mandatory washout
Rationale: Combining sacubitril/valsartan with an ACE inhibitor significantly increases bradykinin levels (both agents impair bradykinin degradation via different mechanisms), dramatically increasing the risk of potentially life-threatening angioedema. A mandatory minimum 36-hour washout period from any ACE inhibitor is required before initiating sacubitril/valsartan. The 36-hour window is a specific, testable fact frequently seen on NCLEX pharmacology questions.
Question 4
A nurse reviews morning labs for a patient with heart failure on furosemide 80 mg PO daily and digoxin 0.125 mg PO daily. Results: K+ 3.0 mEq/L, digoxin level 0.8 ng/mL. What is the nurse’s priority action?
A) Administer both medications – the digoxin level is within the therapeutic range B) Hold the digoxin, notify the provider, and anticipate a potassium replacement order C) Administer the furosemide and reassess potassium in 4 hours D) Hold both medications and wait for a provider to reassess the patient
Answer: B – hold digoxin, notify provider, anticipate potassium replacement
Rationale: Even at a therapeutic digoxin level (0.8 ng/mL is within the 0.5–0.9 range), hypokalemia dramatically potentiates digoxin toxicity. Potassium competes with digoxin for the Na-K-ATPase binding site – when potassium is low, digoxin binds more avidly and toxic effects occur at lower serum levels. A K+ of 3.0 mEq/L (normal 3.5–5.0) is significantly low and must be corrected before administering digoxin. The nurse should hold digoxin, notify the provider, and anticipate K+ replacement. Administering furosemide (C) would worsen hypokalemia. See the electrolyte imbalances nursing reference for potassium replacement guidance.
Question 5
A patient with heart failure is classified as “cold and wet” (Nohria-Stevenson profile C). Which hemodynamic picture is consistent with this classification?
A) Adequate perfusion, significant congestion – warm extremities, crackles, edema B) Impaired perfusion, significant congestion – cool extremities, hypotension, crackles, oliguria C) Impaired perfusion, minimal congestion – cool extremities, hypotension, no significant edema D) Adequate perfusion, no congestion – stable outpatient
Answer: B – cold and wet = impaired perfusion + congestion
Rationale: The Nohria-Stevenson bedside profiles categorize ADHF patients by perfusion adequacy (warm vs cold) and congestion (wet vs dry). “Cold and wet” describes impaired forward perfusion (cool extremities, hypotension, oliguria, altered mentation) combined with significant congestion (crackles, elevated JVD, edema). This is the highest-risk ADHF profile and typically requires inotropic support and ICU-level care – aggressive diuresis alone would worsen hypoperfusion. Option A describes “warm and wet” (the most common ADHF presentation). Option C is “cold and dry.” Option D is “warm and dry” (compensated HF).
Question 6
A nurse is teaching a patient with heart failure about home monitoring. Which statement by the patient requires the nurse to provide additional teaching?
A) “I will weigh myself every morning before I eat or drink anything.” B) “I will call my doctor if I gain 2 pounds in one day or 5 pounds in one week.” C) “I can wait to call my doctor until I feel short of breath – that’s when HF is getting worse.” D) “I will check food labels for sodium and stay within the limit my provider gave me.”
Answer: C – weight gain precedes dyspnea; do not wait for symptoms
Rationale: The critical teaching point is that weight gain from fluid retention occurs before shortness of breath develops. Daily weights are a leading indicator of decompensation – acting on weight gain early can prevent hospitalization. Patients should call their provider at the weight thresholds (2 lbs/day or 5 lbs/week), not wait for dyspnea. All other statements are correct: morning weights before eating (A), both weight thresholds (B), and following the prescribed sodium limit (D).
Related references
- Atrial fibrillation nursing reference – AFib is both a trigger for decompensation and a common complication of heart failure; rate control and anticoagulation
- Hypertension nursing reference – leading cause of HFpEF; hypertensive urgency and emergency can precipitate acute decompensation
- EKG interpretation cheat sheet – rhythm monitoring in heart failure: AFib, ventricular arrhythmias, QTc prolongation with electrolyte disturbances
- Nursing lab values cheat sheet – BNP and NT-proBNP thresholds, electrolyte reference ranges, digoxin therapeutic level
- Electrolyte imbalances nursing reference – loop diuretics cause hypokalemia and hypomagnesemia; aldosterone antagonists cause hyperkalemia; hypokalemia potentiates digoxin toxicity
- ABG interpretation reference – respiratory and metabolic compensation in acute pulmonary edema and low-output states
- Sepsis nursing reference – sepsis is a major precipitant of acute decompensation; myocardial depression in sepsis
This article is for educational purposes only. Always apply clinical judgment and follow your institution’s evidence-based protocols when caring for patients with heart failure.
References
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263–e421. doi:10.1016/j.jacc.2021.12.012
- McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi:10.1056/NEJMoa1409077
- Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–1658. doi:10.1056/NEJM200105313442201
- Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709–717. doi:10.1056/NEJM199909023411001
- Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21. doi:10.1056/NEJMoa1009492
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi:10.1056/NEJMoa1911303
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368 – source for the oxygen threshold (SpO2 < 90% or PaO2 < 60 mmHg), the class III recommendation against routine opiates, and the diuretic-response targets. Updated by the 2023 focused update (McDonagh TA, et al. Eur Heart J. 2023;44(37):3627–3639. doi:10.1093/eurheartj/ehad195).
- Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2013;62(16):e147–e239. doi:10.1016/j.jacc.2013.05.019 – superseded by ref 1; listed for historical context only.
- Fonarow GC, Adams KF, Abraham WT, Yancy CW, Boscardin WJ; ADHERE Scientific Advisory Committee. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293(5):572–580. doi:10.1001/jama.293.5.572
- Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. doi:10.1056/NEJMoa2022190
- Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–548. doi:10.1056/NEJMoa1812851
- Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161–167. doi:10.1056/NEJMoa020233
- Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805. doi:10.1056/NEJMoa1005419
- Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–1331. doi:10.1001/jama.297.12.1319
- Ignatavicius DD, Workman ML, Rebar CR. Medical-Surgical Nursing: Concepts for Interprofessional Collaborative Care. 10th ed. St. Louis, MO: Elsevier; 2021.
- Palaniappan LP, Allen NB, Almarzooq ZI, et al. 2026 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2026;153(9):e275–e906. doi:10.1161/CIR.0000000000001412
- Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112(25):3958–3968. doi:10.1161/CIRCULATIONAHA.105.590091
- Peacock WF, Hollander JE, Diercks DB, Lopatin M, Fonarow G, Emerman CL. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J. 2008;25(4):205–209. doi:10.1136/emj.2007.050419 – source for the association between morphine and increased mechanical ventilation, ICU admission, and mortality in ADHF.
- Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41(10):1797–1804. doi:10.1016/S0735-1097(03)00309-7
- Forrester JS, Diamond G, Chatterjee K, Swan HJ. Medical therapy of acute myocardial infarction by application of hemodynamic subsets (first of two parts). N Engl J Med. 1976;295(24):1356–1362. doi:10.1056/NEJM197612092952406
- Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction (EPHESUS). N Engl J Med. 2003;348(14):1309–1321. doi:10.1056/NEJMoa030207
- Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction (EMPEROR-Preserved). N Engl J Med. 2021;385(16):1451–1461. doi:10.1056/NEJMoa2107038
- Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction (DELIVER). N Engl J Med. 2022;387(12):1089–1098. doi:10.1056/NEJMoa2206286
- Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction (FINEARTS-HF). N Engl J Med. 2024;391(16):1475–1485. doi:10.1056/NEJMoa2407107
- Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938–1952. doi:10.1016/S0140-6736(22)02076-1
- Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391–1400. doi:10.1016/S0140-6736(22)00369-5
- O’Driscoll BR, Howard LS, Earis J, Mak V. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017;72(Suppl 1):ii1–ii90. doi:10.1136/thoraxjnl-2016-209729
- Ewy GA. The abdominojugular test: technique and hemodynamic correlates. Ann Intern Med. 1988;109(6):456–460. doi:10.7326/0003-4819-109-6-456
- Gorodeski EZ, et al. HF STATS 2026: an updated report on heart failure epidemiology and outcomes from the Heart Failure Society of America. J Card Fail. 2026. doi:10.1016/j.cardfail.2026.07.009
- US National Library of Medicine. DailyMed prescribing information: Kerendia (finerenone), DigiFab (digoxin immune fab, ovine), Farxiga (dapagliflozin), Jardiance (empagliflozin), furosemide injection, and lisinopril (boxed warning: fetal toxicity). Accessed October 12, 2026. https://dailymed.nlm.nih.gov/